Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07197723 · ClinicalTrials.gov registry record
Study of How People Make Decisions About Prostate Cancer Risk
A clinical trial of BRCA1/2 and Geneitic Testing, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT07197723: Recruiting study of BRCA1/2 and Geneitic Testing, sponsored by Memorial Sloan Kettering Cancer Center.
NCT07197723 is a study of BRCA1/2 and Geneitic Testing that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 150 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07197723, a study of BRCA1/2 and Geneitic Testing, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn how people with BRCA1/2 mutations respond to genetic risk modifier testing. The researchers will learn more about how people make choices about their health care, including about methods to screen for prostate cancer. Researchers are also doing this study to learn about how the genetic risk modifier test affects people's thoughts and feelings.
Primary Outcome
Change in intention for each screening option measured with the Choice predisposition scale. Choice Predisposition scale ranges from 1 (leaning towards yes) to 15 (leaning towards no) regarding a specific option.
Conditions Studied
Interventions
- OTHER Assessments
- GENETIC cheek (buccal) swab
- OTHER optional collection of blood
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-09-25 |
| Est. Completion | 2027-09 |
What NCT07197723 shows while recruiting
NCT07197723 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 2 conditions, with BRCA1/2 appearing as the primary indexed condition, and to 3 interventions - of which Assessments is the first listed.
NCT07197723 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07197723 about?
NCT07197723 is a clinical study titled "Study of How People Make Decisions About Prostate Cancer Risk". The purpose of this study is to learn how people with BRCA1/2 mutations respond to genetic risk modifier testing. The researchers will learn more about how people make choices about their health care, including about methods to screen for prostate cancer. Researchers are also doing this study to lea...
What is the current status of trial NCT07197723?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2025-09-25. Estimated completion is 2027-09.
What conditions does trial NCT07197723 study?
This clinical trial studies the following conditions: BRCA1/2, Geneitic Testing.
What interventions are being tested in trial NCT07197723?
The interventions under investigation include: Assessments (OTHER), cheek (buccal) swab (GENETIC), optional collection of blood (OTHER).
Who is sponsoring clinical trial NCT07197723?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07197723 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for BRCA1/2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI